)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Corline Biomedical
Corline Biomedical (CLBIO) investor relations material
Corline Biomedical Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary26 Aug, 2026
Executive summary
Net sales for H1 2026 reached 8,978 KSEK, more than doubling from 4,242 KSEK in H1 2025, already surpassing full-year 2025 sales.
The company is in an early expansion phase, driven by customer Kardium's launch of the Globe catheter in the US, Canada, and other markets.
Positive operational and total cash flow was achieved in Q2 2026, reflecting strong cost control and financial discipline.
Strategic focus is on scaling US market presence and supporting anticipated volume growth from Kardium.
Financial highlights
Q2 2026 net sales: 4,687 KSEK (Q2 2025: 2,187 KSEK); H1 2026 net sales: 8,978 KSEK (H1 2025: 4,242 KSEK).
Q2 2026 result after financial items: -1,435 KSEK (Q2 2025: -3,257 KSEK); H1 2026: -3,936 KSEK (H1 2025: -6,328 KSEK).
Earnings per share H1 2026: -0.15 SEK (H1 2025: -0.26 SEK).
Cash and cash equivalents at June 30, 2026: 32,994 KSEK (June 30, 2025: 8,322 KSEK).
Equity at period end: 99,001 KSEK (80,586 KSEK); equity ratio: 86.7% (93.3%).
Outlook and guidance
Significant sales growth expected as Kardium expands commercial presence and market penetration.
Investment program underway to increase reagent production volume 20-fold to meet anticipated demand.
Plan to recruit or convert 3–5 major customers to commercial phase by 2029 in prioritized market segments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Corline Biomedical
- Record commercial sales and Kardium partnership drive growth and margin improvement.CLBIO
Q1 2026 - First US commercial use of CHS™ and strong financing set stage for 2026 growth.CLBIOQ4 2025
- Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth.CLBIOQ3 2025
- Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales.CLBIOQ2 2025
- Sharply reduced costs and strategic focus position Corline for growth and profitability by 2025.CLBIOQ3 2024
- Revenue down, losses widened, but US launch and new projects drive future potential.CLBIOQ2 2024
- Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism.CLBIOQ1 2025
- 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®.CLBIOQ4 2024
Next Corline Biomedical earnings date
Q3 202616 Nov, 2026
Corline Biomedical
Next Corline Biomedical earnings date
Q3 202616 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage